Announced

Completed

Talaris Therapeutics completed the merger with Tourmaline Bio.

Synopsis

Talaris Therapeutics, a biotechnology company, completed the merger with Tourmaline Bio, a late-stage clinical biotechnology company. Financial terms were not disclosed. “We are thrilled to close this transaction and move Tourmaline into its next phase as a public company, leading an IL-6 renaissance and continuing to accelerate TOUR006 through late-stage clinical trials in TED, ASCVD and other diseases,” Sandeep Kulkarni, Tourmaline Managing Director and CEO.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US